Last reviewed · How we verify

NCT04096222

Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients

Status unknown Last updated 10 August 2022
What this trial tests

trial in Pemphigus Vulgaris in 42 participants. Status unknown.

Timeline
29 June 2021
Primary endpoint
28 March 2023
28 March 2023

Quick facts

Lead sponsorInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment42
Start date29 June 2021
Primary completion28 March 2023
Estimated completion28 March 2023
Sites2 locations across Mexico

Conditions studied

Sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran — full company profile →

Who can join

18 and older, any sex, with Pemphigus Vulgaris or Bullous Dermatoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will compare the pattern of Th17 immune response in active and inactive pemphigus subjects. Skin and serum samples will be taken at the moment of enrollment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04096222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing